Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs DexCom, Inc. (DXCM) Price & Performance

Bristol-Myers Squibb CoTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs DexCom, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.66 (market cap $129.94B), while DexCom, Inc. trades at $89.96 (market cap $33.79B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.8× DexCom, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.

BMYDXCM
Market Cap
$129.94B$33.79B
Sector
HealthHealth
52-Week High
$65.89$89.53
52-Week Low
$42.60$54.84
Enterprise Value
$163.92B$33.24B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.

BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.

DexCom, Inc.

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM